Discovering and developing first-in-class medicines that address medical conditions prevalent in old age
Location: United States, California, Oakland
Employees: 11-50
Total raised: $70M
Founded date: 2021
Investors 2
| Date | Name | Website |
| 25.07.2023 | TCG Crosso... | tcgcrossov... |
| - | Atlas Vent... | atlasventu... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 01.09.2021 | Series A | $70M | Atlas Vent... |
Mentions in press and media 6
| Date | Title | Description |
| 29.03.2024 | A new Ozempic rival helps patients lose fat, but keep their muscle — the holy grail for a weight-loss drug | Health A new Ozempic rival helps patients lose fat, but keep their muscle — the holy grail for a weight-loss drug Hilary Brueck 2024-03-29T16:38:44Z Share icon An curved arrow pointing right. Share Facebook Icon The letter F. Facebook Email... |
| 14.07.2023 | Big Bucks For Obesity Treatments As Eli Lilly Buys Versanis Bio For Up To $1.9B | 1 Share Email Facebook Twitter LinkedIn Pharma giant Eli Lilly announced today that it is buying Versanis Bio, a startup developing drugs with applications in obesity treatment, in a transaction valued at up to $1.93 billion. Lilly did not ... |
| 01.09.2021 | Versanis Bio lands $70M | Versanis Bio has raised a $70 million Series A co-led by Atlas Venture and Medicxi. The Oakland, Calif.-based company develops therapeutics for the treatment of conditions common in older adults, including metabolic disease and obesity. Add... |
| 31.08.2021 | Versanis Bio Raises $70M in Series A Financing | Versanis Bio, an Oakland, Calif.-based company established to discover and develop first-in-class medicines that address medical conditions prevalent in older adults, closed a $70m Series A financing. The round was co-led by Atlas Venture a... |
| 31.08.2021 | Versanis Bio : Announces $70 Million Series A Financing to Advance Bimagrumab for the Treatment of Obesity | Versanis Bio today announced the closing of its Series A financing of $70 million to advance the clinical development of bimagrumab, an activin receptor type II antagonist. The company was founded and seeded earlier this year by biotech inv... |
| - | Obesity drug maker Versanis to be bought by Eli Lilly for $1.9 billion | Eli Lilly will acquire Versanis, a privately held obesity drug maker, for up to $1.93 billion to expand its weight loss treatment portfolio. The deal is Eli Lilly’s latest attempt to capitalize on the weight loss industry gold rush, which b... |